Cáncer de próstata: biomarcadores prometedores relacionados con la enfermedad agresiva / Prostate Cancer: Promising Biomarkers Related to Aggressive Disease

Antecedentes: A pesar del número rápidamente creciente de marcadores biológicos de pronóstico y/o respuesta a tratamientos específicos posibles en el cáncer de próstata, ninguno ha mostrado hasta la fecha la capacidad de pronosticar por completo el cáncer de próstata en la urología basada en la evidencia. Objetivo: Revisar la literatura pertinente sobre el tema. Adquisición de evidencia: Se llevó a cabo una revisión exhaustiva de la literatura actual centrándose en los prometedores biomarcadores relacionados con el cáncer de próstata agresivo. Resumen de la evidencia: En combinación con la naturaleza heterogénea de la enfermedad, las series de casos mixtas son el diseño de estudio más común, que impiden resultados sólidos y el desarrollo de una estrategia terapéutica eficaz. La mejora de la supervivencia del paciente con cáncer de próstata requiere no solo la identificación de un nuevo objetivo terapéutico, basado en la comprensión detallada de los mecanismos biológicos implicados en la diseminación metastásica y el crecimiento del tumor, sino también consistentes estudios clínicos. Conclusión: Se necesita un mejor diseño de estudio implicando los marcadores potenciales e incluyendo a los pacientes bien clasificados y por estadios, con una metodología sólida y los resultados adecuados (sobre todo la supervivencia) para la evolución en este campo (AU)

Background: Although a rapidly growing number of candidate biological markers of prognosis and/or response to specific treatments in prostate cancer, none have to date showed ability to completely prognosticate prostate cancer on evidence based urology. Objective: To review the pertinent literature on the issue. Acquisition of evidence: A comprehensive review of the current literature was done focusing on promising biomarkers related to aggressive prostate cancer. Summary of evidence: Combined with the heterogeneous nature of the disease, mixt case series are the most common study design, impeding robust results and the development of an effective therapeutic strategy. Improvement in prostate cancer patient survival requires not only the identification of new therapeutic target based on detailed understanding of the biological mechanisms involved in metastatic dissemination and tumor growth but strong clinical studies as well. Conclusion: Better study design involving potential markers and including well-classified and staged patients with robust methodology and adequate outcomes (mainly survival) are necessary to the field evolution (AU)

[Prostate cancer: promising biomarkers related to aggressive disease]. / Cáncer de próstata: biomarcadores prometedores relacionados con la enfermedad agresiva.

BACKGROUND: Although a rapidly growing number of candidate biological markers of prognosis and/or response to specific treatments in prostate cancer, none have to date showed ability to completely prognosticate prostate cancer on evidence based urology. OBJECTIVE: To review the pertinent literature on the issue. ACQUISITION OF EVIDENCE: A comprehensive review of the current literature was done focusing on promising biomarkers related to aggressive prostate cancer. SUMMARY OF EVIDENCE: Combined with the heterogeneous nature of the disease, mixed case series are the most common study design, impeding robust results and the development of an effective therapeutic strategy. Improvement in prostate cancer patient survival requires not only the identification of new therapeutic target based on detailed understanding of the biological mechanisms involved in metastatic dissemination and tumor growth but strong clinical studies as well. CONCLUSION: Better study design involving potential markers and including well-classified and staged patients with robust methodology and adequate outcomes (mainly survival) are necessary to the field evolution.